CanSino adds mRNA with Precision NanoSystems
CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems.
The partners will work on an mRNA nanoparticle vaccine for COVID-19, with Precision NanoSystems designing the vaccine and CanSino undergoing preclinical and clinical development, regulatory activities and commercialization. CanSino has the commercialization rights for the vaccine in Asia- except Japan- while Vancouver-based, Precision holds onto the rights for the rest of the world.
Moderna became the first biopharma to...
